Vero Biotech

VERO Biotech is a private, commercial-stage biotech company based in Atlanta, Georgia, founded in 2016. The company has developed and gained FDA approval for its GENOSYL® Delivery System, a novel, tankless inhaled nitric oxide delivery device approved for use across all areas of care, including acute care, anesthesia, MRI, and inter-hospital transport. Backed by significant venture funding and recognized with industry awards, VERO is focused on commercializing its platform to address unmet needs in critical care. The company operates with a direct commercialization and support model, reinforced by its Partnership365™ service program.

GENOSYL® Delivery System (DS): A tankless, on-demand inhaled nitric oxide (iNO) delivery platform that generates NO gas from a proprietary solid chemical source (NORM™ cartridges) at the point of care. It is designed for use across all care settings (ICU, OR, MRI, transport) without device changes.

VERO competes in the inhaled nitric oxide delivery market against dominant players like Mallinckrodt (INOmax®), which uses traditional cylinder-based systems. Its competitive edge is its tankless, multi-setting platform, which addresses logistical and safety drawbacks of cylinders. It also faces competition from other potential new delivery technologies and generic NO entrants.